Treatment of High-Risk Cerebral Primitive Neuroectodermal Tumors in Children Aged Over 5 Years

Phase 2 Completed 68 enrolled Gustave Roussy, Cancer Campus, Grand Paris

NaSingle-groupOpen-labelTreatment

Summary

Primary objective : To increase the 3 year progression-free survival from 40% to 60%. Patients included : metastatic, cerebral primitive neuroectodermal tumors in children aged over 5 years.

Timeline

Start: 2009-01
Primary completion: 2012-01
Completion: 2012-01

Publications

Larrouquere L, Dufour C, Faure-Conter C, Alapetite C, Meyronet D, Bolle S, Bonneville-Levard A, Sunyach MP, Laurence V, Frappaz D. Intensive pediatric chemotherapy regimen (PNET HR+5) in adult high-risk medulloblastoma and pineoblastoma patients. Neurooncol Adv. 2024 Aug 10;6(1):vdae141. doi: 10.1093/noajnl/vdae141. eCollection 2024 Jan-Dec.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Carboplatin	Small molecule	160 mg/m2	Other
Subject	Etoposide	Small molecule	100 mg/m2	Other
Subject	Thiotepa	Other / unclassified	200 mg/m2	Other

Treatment of High-Risk Cerebral Primitive Neuroectodermal Tumors in Children Aged Over 5 Years

Summary

Timeline

Publications

Drugs

Indications